Psychopharmacogenetic basis of medication-induced movement disorders

International Clinical Psychopharmacology

Volumn 12, Issue 1, 1997, Pages 1-12

  Tu, J B ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b London Psychiatric Hospital   (Canada)

Author keywords

Movement disorders; Psychopharmacogenetics

Indexed keywords

BARBITURIC ACID DERIVATIVE; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADVERSE DRUG REACTION; BASAL GANGLION; HUMAN; MOTOR DYSFUNCTION; NEUROBIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 0030946347     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199701000-00001     Document Type: Review

References (128)

1. Abramowicz M (1989) Drugs that cause psychiatric symptoms. In: The Medical Letter on Drugs and Therapeutics, vol 31 (Ed. M Abramowicz). The Medical Letter, New York, 113-118.
2. Adler CH, Wrabetz L, Brin MF and Hurtig HI (1994) Cerebellar ataxia, dystonia, and tremor within a family with variable phenotypes of a single genetic disorder. Movement Disorders, 9, 155-160.
3. Armstrong M, Daly AK, Cholerton S, Bateman DN and Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet, 339, 1017-1018.
4. Aronson TA (1985) Persistent drug-induced parkinsonism. Biological Psychiatry, 20, 795-798.
5. Arpa J, Morale SC, Molina MG, Caminero AB, Lara M and Barreiro P (1994) Neuroleptic malignant syndrome and Kuf's disease. Archives de Neurobiologia (Madrid), 57, 36-40.
6. Arthur H, Dahl ML, Siwers B and Sjöqvist F(1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. Journal of Clinical Psychopharmacology, 15, 211-216.
7. Arya DK (1994) Extrapyramidal symptoms with selective serotonin reuptake inhibitors. British Journal of Psychiatry, 165, 728-733.
8. Barton A, Bowie J and Ebmeier K (1990) Low plasma iron status and akathisia. Journal of Neurology, Neurosurgery, and Psychiatry, 53, 671-674.
9. Bowers MB and Swigar ME (1988) Psychotic patients who become worse on neuroleptics. Journal Clinical Psychopharmacology, 8, 417-421.
10. Britto MR and Wedlund PJ (1992) Cytochrome P-450 in the brain: potential evolutionary and thereapeutic relevance of localization of drug-metabolizing enzymes. Drug Metabolism and Disposition, 20, 446-450.
11. Brooks DJ (1991) Detection of preclinical Parkinson's disease with PET. Neurology, 41 (suppl 2), 24-27.
12. Buchsbaum MS (1990) Frontal lobes, basal ganglia, temporal lobes - three sites for schizophrenia? Schizophrenia Bulletin, 16, 377-389.
13. Buckley P, Carmody E and Hutchinson M (1990) Wilson's disease and the neuroleptic malignant syndrome. Irish Journal of Psychological Medicine, 7, 138-139.
14. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K and Willner JH (1981) Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology, 31, 1022-1026.
15. Casey DE (1995) Motor and mental aspects of extrapyramidal syndromes. International Clinical Psychopharmacology, 10, (suppl 3), 105-114.
16. Caligiuri MP, Lohr JB and Jeste DV (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. American Journal of Psychiatry, 150, 1343-1348.
17. Carroll BT and Goforth HW (1995) Serum iron in catatonia. Biological Psychiatry, 38, 775-777.
18. Chadwick D, Reynolds and Marsden CD (1976) Anticonvulsants-induced dyskinesia: a comparison with dyskinesias induced by neuroleptics. Journal of Neurology, Neurosurgery, and Psychiatry, 39, 1210-1218.
19. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M and Liberman JA (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 53, 313-319.
20. Chengappa KNR, Baker RW, Baird J (1993) Iron for chronic and persistent akathisia? Journal of Clinical Psychiatry, 54, 320-321.
21. Cutler P (1994) Iron overload and psychiatric illness. Canadian Journal of Psychiatry, 39, 8-11.
22. Devor EJ (1990) Untying the gordian knot: the genetics of Tourette syndrome. Journal of Nervous and Mental Disease, 178, 669-679.
23. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P and Marsden CD (1990) Decreased ferritin levels in brain in Parkinson's disease. Journal of Neurochemistry, 55, 16-20.
24. Ekbom KA (1960) Restless legs syndrome. Neurology, 10, 868-873.
25. Evans DAP, Mahgoub A, Sloan TP, Idle JR and Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17, 102-105.
26. Factor SA, Molho ES, Podskalny GD and Brown D (1995) Parkinson's disease: drug-induced psychiatric states. In: (Eds Weiner WJ and Lange AE), pp. 115-138. Behavioural Neurology of Movement Disorders. Raven Press Ltd, New York.
27. Farrer LA, Bowcock AM, Hebert JM, Bonne-Tamir B, Sternlieb I, Giagheddu M, St George-Hyslop P, Frydman M, Lössner J. (1991) Predictive testing for Wilson's disease using tightly linked and flanking DNA markers. Neurology, 41, 992-999.
28. Fink M (1995) Recognizing NMS as a type of catatonia. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 8, 75-76.
29. Fisher CM (1989) 'Catatonia' due to disulfiram toxicity. Archives of Neurology, 46, 798-804.
30. Francis A and Freeman H (1984) Psychiatric abnormality and brain calcification over four generations. Journal of Nervous and Mental Disease, 172, 166-170.
31. Galdi J, Rieder R, Silber D and Bonato R (1981) Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychological Medicine, 11, 713-728.
32. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, Samson JA and Conley C (1994) Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry, 151, 836-841.
33. Garrod AE (1931) The Inborn Factors in Disease. Clarendon Press, Oxford.
34. Gelenberg AJ and Jefferson JW (1995) Lithium tremor. Journal of Clinical Psychopharmacology, 56, 283-287.
35. Gibb WRG (1988) Neuroleptic malignant syndrome in striatonigral degeneration. British Journal of Psychiatry, 153, 254-255.
36. Goetz CG (1983) Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology, 40, 325-326.
37. Gu XF, De Rooij FWM de, Voortman G, Te Velde K, Deybach JC, Nordmann Y and Grandchamp B (1994) Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis. Human Genetics, 93, 47-52.
38. Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC and Smith M (1995) Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. American Journal of Psychiatry, 152, 191-196.
39. Höck A, Demmel U, Schicka H, Kaperek K and Feinendegen LE (1975) Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium. Brain, 98, 49-64.
40. Hoffman WF, Labs SM and Casey DE (1987) Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry, 22, 427-439.
41. Holzman PS, Kringlen E, Matthysse S, Flanagan D, Lipton RB, Cramer G, Levin S, Lange K and Levy DL (1988) A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. Archives of General Psychiatry, 45, 641-647.
42. Hoogenraad TU, Van Hattum J and Van den Hamer CJA (1987) Management of Wilson's disease with zinc sulphate: experience in a series of 27 patients. Journal of Neurological Science, 77, 137-146.
43. Horiguchi J (1991) Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment. Acta Psychiatrica Scandinavica, 84, 301-303.
44. Hosty G (1992) Neuroleptic malignant syndrome in two sisters. Irish Journal of Psychological Medicine, 9, 122-123.
45. Hotamisligil GS, Girmen S, Fink JS, Tivol E, Shalish C, Trofatter J, Baenziger J, Diamond S, Markham C, Sullivan J, Growdon J and Breakefield XO (1994) Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease. Movement Disorders, 9, 305-310.
46. Ishikawa A and Miyataka T (1995) A family with hereditary juvenile dystonia-parkinsonism. Movement Disorders, 10, 482-488.
47. Jones HR and Hedley-Whyte T (1983) Idiopathic haemochromatosis (IHC). Dementia and ataxia as presenting signs. Neurology, 33, 1479-1483.
48. Kalow W (1990) Pharmacogenetics: Past and future. Life Sciences, 47, 1385-1397.
49. Kalow W (1993) Pharmacogenetics: Its biologic roots and the medical challenge. Clinical Pharmacology and Therapeutics, 54, 235-241.
50. Kalow W and Gunn DR (1957) The relation between dose of succinylcholine and duration of apnea in man. Journal of Pharmacology and Experimental Therapeutics, 120, 203-214.
51. Keeper GA and Casey DE (1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. American Journal of Psychiatry, 148, 85-89.
52. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS and Callahan AM (1995) The emerging role of cytochrome P450 3A in psychopharmacology. Journal of Clinical Psychopharmacology, 15, 387-398.
53. Khot V and Wyatt R (1991) Not all that moves is tardive dyskinesia. American Journal of Psychiatry, 148, 661-666.
54. Klawans HL (1987) Chorea. Canadian Journal of Neurological Science, 14, 536-540.
55. Kontaxakis V, Stefanis C, Maridis M, Tserpe V (1988) Neuroleptic malignant syndrome in a patient with Wilson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 51, 1001-1021.
56. Kushnir SL and Ratner JT (1989) Calcium channel blockers for tardive dyskinesia in geriatric psychiatric patients. American Journal of Psychiatry, 146, 1218-1219.
57. Laplane D, Levasseur M, Pillon B, Dubois B, Baulac M, Mazoyer B, Dinh ST, Sette G, Danze F and Baron JC (1989) Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. Brain, 112, 699-725.
58. Lauterbach EC, Spears TE, Prewett MJ, Price ST, Jackson JG and Kirsh AD (1994) Neuropsychiatrie disorders, myoclonus and dystonia in calcification of basal ganglia pathways. Biological Psychiatry, 35, 345-351.
59. LeWitt PA, Walters A, Hening W and McHale D (1993) Persistent movement disorders induced by buspirone. Movement Disorders, 8, 331-334.
60. Lowe TL, Cohen DJ, Detlor J, Kremenitzer M and Shatywitz BA (1982) Stimulant medications precipitate Tourette's Syndrome. Journal of American Medical Association, 247, 1729-1731.
61. McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootam N and Menon MS (1996) Abnormal movements in never-medicated Indian patients with schizophrenia. British Journal of Psychiatry, 168, 221-226.
62. McGeer PL, McGeer EG, Itagaki S and Mizukawa K (1987) Anatomy and pathology of the basal ganglia. The Canadian Journal of Neurological Science, 14, 363-372.
63. McKeith I, Fairbairn A, Perry R, Thompson P and Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal, 305, 673-678.
64. McKusick VA (1957) Mechanisms in genetic diseases of man. American Journal of Medicine, 22, 676-686.
65. Meterissian GS (1996) Risperidone-induced neuroleptic malignant syndrome: a case report and review. Canadian Journal of Psychiatry, 41, 52-54.
66. Micheli FE, Pardal MMF, Giannaula R, Gatto M, Parera IC, Paradiso G, Torres M, Pikielny R and Pardal JF (1989) Movement disorders and depression due to flunarizine and cinnarizine. Movement Disorders, 4, 139-146.
67. Miller LG and Jankovic J (1992) Drug-induced movement disorders: an overview. In: Movement Disorders in Neurology and Neuropsychiatry (Eds A Joseph and R Young). Blackwell Scientific, Boston, 5-32.
68. Mizuta E, Yamasaki S, Nakatake M and Kuno S (1993) Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology, 43, 1048-1049.
69. Moore AP, MacFarlane IA, Blumhartdt LD (1990) Neuroleptic malignant syndrome and hypothyroidism. Journal of Neurology, Neurosurgery and Psychiatry, 53, 517-518.
70. Moore MR, McColl KEL, Rimington C and Goldberg A (1987) Disorders of Porphyrin Metabolism. Plenum Medical Book Co., New York.
71. Motulsky AG (1957) Drug reactions, enzymes and biochemical genetics. Journal of American Medical Association, 165, 835-837.
72. Müller N, Voderholzer U, Kurtz G and Straube A (1994) Tourette's syndrome associated with restless legs syndrome and akathisia in a family. Acta Neurologica Scandinavica, 89, 429-432.
73. Myrianthopoulos N, Kurland AA and Kurland LT (1962) Hereditary predisposition in drug-induced parkinsonism. Archives of Neurology, 6, 19-23.
74. O'Loughlin V, Dickie AC and Ebmeier KP (1991) Serum iron and transferrin in acute neuroleptic-induced akathisia. Journal of Neurology, Neurosurgery and Psychiatry, 54, 363-364.
75. Okano Y, Eisensmith RC, Güttler F, Lichter-Konecki U, Konecki DS, Trefz FK, Dasovich M, Wang T, Henriksen K, Lou H and Woo SLC (1991) Molecular basis of phenotypic heterogeneity in phenylketonuria. New England Journal of Medicine, 324, 1232-1238.
76. Otani K, Horiuchi M, Kondo T, Kaneko S and Fukushima Y (1991) Is the predisposition to neuroleptic malignant syndrome genetically transmitted? British Journal of Psychiatry, 158, 850-853.
77. Owens DGC and Johnstone EC (1982) Spontaneous involuntary disorders of movement. Archives of General Psychiatry 32, 452-461.
78. Pantelis C, Barnes TRE and Nelson HE (1992) Is the concept of frontal-subcortical dementia relevant to schizophrenia. British Journal of Psychiatry, 160, 442-460.
79. Patience DA, Blackwood DHR, McColl KEL and Moore MR (1994) Acute intermittent porphyria and mental illness-a family study. Acta Psychiatrica Scandinavica, 89, 262-267.
80. Penrose LS (1966) The contribution of mental deficiency research to psychiatry. British Journal of Psychiatry, 112, 747-755.
81. Peterson BS (1996) Consideration of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Journal of Clinical Psychiatry, 57, (suppl 9), 24-34.
82. Powers P, Douglas TS and Waziri R (1976) Hyperpyrexia in catatonic states. Diseases of the Nervous System, 37, 359-361.
83. Richardson M, Haugland G and Craig T (1991) Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. American Journal of Psychiatry, 148, 1322-1328.
84. Rogers D (1992) Motor Disorder in Psychiatry. Towards a Neurological Psychiatry. Wiley & Sons, Chichester.
85. Rosebush PI, MacQueen GM, Clarke JTR, Callahan JW and Mazurek MF (1995) Late-onset Tay-Sacks disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Journal of Clinical Psychiatry, 56, 347-353.
86. Rosebush PI and Mazurek MF (1991) Serum iron and neuroleptic malignant syndrome. Lancet, 338, 149-151.
87. Sachdev P (1992) Drug-induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry, 26, 242-248.
88. Sachdev P (1993) The neuropsychiatry of brain iron. Journal of Neuropsychiatry and Clinical Neurosciences, 5, 18-19.
89. Sachdev P and Kruk J (1994) Clinical characteristics and predisposing factors in acute drug-induced akathisia. Archives of General Psychiatry, 51, 963-974.
90. Sachdev P, Kruk J, Kneebone M and Kissane D (1995) Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. Journal of Clinical Psychopharmacology, 15, 365-371.
91. Sandyk R (1990) Zinc deficiency in attention-deficit hyper-activity disorder. International Journal of Neuroscience, 52, 239-241.
92. Sandyk R, Kay SR, Awerbuch GI and Iacono RP (1991) Risk factors for neuroleptic-induced movement disorders. International Journal of Neurosciences, 61, 149-188.
93. Santosh PJ and Malhotra S (1994) Varied psychiatric manifestations of acute intermittent porphyria. Biological Psychiatry, 36, 744-747.
94. Sedvall G and Farde L (1995) Chemical brain anatomy in schizophrenia. Lancet, 346, 743-749.
95. Singer HS, Hahn IH and Moran TH (1991) Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology, 30, 558-562.
96. Simpson JSA (1996) Familial akathisia and depression treated with nefazodone. Canadian Journal of Psychiatry, 41, 539-540.
97. Starkstein SE, Robinson RG, Berthier ML, Raikh RM and Price TR (1988) Differential mood changes following basal ganglia vs thalamic lesions. Archives of Neurology, 45, 725-730.
98. Streifler J. Golomb M and Gadoth N (1989) Psychiatric features of adult GM2 gangliosis. British Journal of Psychiatry, 155, 410-413.
99. Suranyi-Cadotte BE, Nestoros JN, Nair NPV, Lal S and Gauthier S (1985) Parkinsonism induced by high doses of diazepam. Biological Psychiatry, 20, 451-460.
100. Susman VL and Addonizio G (1987) Reinduction of neuroleptic malignant syndrome by lithium. Journal of Clinical Psychopharmacology, 7, 339-341.
101. Swift RG, Perkins DO, Chase CL, Sadler DB and Swift M (1991) Psychiatric disorders in 36 families with Wolfram syndrome. American Journal of Psychiatry, 148, 775-779.
102. Tu JB (1980) Phenylketonuria: the inadvisability of neuroleptic medication. Biological Psychiatry, 15, 795-802.
103. Tu JB (1981) The inadvisability of neuroleptic medication in Wilson's disease. Biological Psychiatry, 16, 963-968.
104. Tu JB (1994) Theory and practice of psychopharmacogenetics. American Journal of Medical Genetics, 54, 391-397.
105. Tu JB (1996) Neuroleptic malignant syndrome: a psychopharmacogenetic perspective. Journal of Child and Adolescent Psychopharmacology, 6, 151-152.
106. Tu JB, Blackwell RQ, Fresh JW and Watten RH (1968) Diagnosis and treatment studies of patients in asymptomatic stages of Wilson's disease. Birth Defect Original Article Series, 4, 114-120.
107. Tu JB, Shafey H and Van Dewetering (1994) Iron deficiency in two adolescents with conduct, dysthymic and movement disorders. Canadian Journal of Psychiatry, 39, 371-375.
108. Van Putten T and Marder SR (1987) Behavioral toxicity of antipsychotic drugs. Journal of Clinical Psychiatry, 48, 13-19.
109. Velamoor VR, Norman RMG, Caroff SN, Mann SC, Sullivan KA and Antelo RE (1994) Progression of symptoms in neuroleptic malignant syndrome. Journal of Nervous and Mental Disease, 182, 168-173.
110. Vogel F and Motulsky AG (1986) Human Genetics: Problems and Approaches. Springer-Verlag, Berlin.
111. Waddington JL and Youssef HA (1988) The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. British Journal of Psychiatry, 153, 376-381.
112. Waddington JL (1989) Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. International Review of Neurobiology, 31, 297-353.
113. Waldenström J (1937) Studien über porphyrie. Acta Medica Scandinavica, 82, (suppl) 1-254.
114. Walshe JM (1988) Diagnosis and treatment of presymptomatic Wilson's disease. Lancet, 2, 435-437.
115. Watson CJ (1975) Hematin and porphyria. New England Journal of Medicine, 283, 605-607.
116. Wegner JT, Catalano F, Gibralter J and Kane JM (1985) Schizophrenics with tardive dyskinesia. Archives of General Psychiatry, 42, 860-865.
117. Weinhold P, Wegner JT and Kane JM (1981) Familial occurrence of tardive dyskinesia. Journal of Clinical Psychiatry, 42, 165-166.
118. White DAC (1992) Catatonia and the neuroleptic malignant syndrome-a single entity? British Journal of Psychiatry, 161, 558-560.
119. Whitelock FA (1982) Symptomatic Affective Disorders: A Study of Depression and Mania Associated with Physical Disease and Medication. Academic Press, Sydney.
120. Wolf U (1995) The genetic contribution to the phenotype. Human Genetics, 95, 127-148.
121. Woodbury MM and Woodbury MA (1992) Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 1161-1164.
122. World Health Organization (1973) Pharmacogenetics, WHO Technical Report. Series No. 524. World Health Organization, Geneva.
123. World Health Organization (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. British Journal of Psychiatry, 156, 412.
124. Yassa H and Annanth J (1981) Familial tardive dyskinesia. American Journal of Psychiatry, 138, 1618-1619.
125. Yassa R, Camille Y and Belzile L (1987) Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. Journal of Clinical Psychopharmacology, 7, 243-246.
126. Yeragani VK, Pohl R, Balon R, Kulkarni A and Keshavan M (1989) Low serum iron levels and tricyclic antidepressant-induced jitteriness. Journal of Clinical Psychopharmacology, 9, 447-448.
127. Yuen O, Caligiuri MP, Williams R and Dickson RA (1996) Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. British Journal of Psychiatry, 168, 702-708.
128. Zorumski CF and Isenberg KE (1991) Insights into the structure and function of GABA-benzodiazepine receptors: iron channels and psychiatry. American Journal of Psychiatry, 148, 162-173.